New Data for Incyte Corporation (INCY)'s Jakafi® (ruxolitinib) Presented at 2012 American Society of Clinical Oncology Annual Meeting
6/5/2012 10:20:02 AM
CHICAGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that analyses from several clinical studies of Jakafi® (ruxolitinib) were presented at the 2012 American Society of Clinical Oncology Annual Meeting from June 1 to 5. Jakafi, an oral JAK1 and JAK2 inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), and is the first and only product to be approved by the FDA for MF. Jakafi is also the first JAK inhibitor to be approved for any indication.